| Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease. | |
| | |
MedLine Citation:
|
PMID: 23199326 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Bullous pemphigoid (BP) is a potentially life-threatening autoimmune blistering disease that is burdened with an increased risk of cardiovascular events. In BP, there is an interplay between inflammation and coagulation both locally, which contributes to skin damage, and systemically, which leads to a prothrombotic state. Fibrinolysis is an important defence mechanism against thrombosis, but has only been studied locally in BP and no systemic data are available. The aim of this observational study was to evaluate systemic fibrinolysis and coagulation activation in patients with BP. We measured parameters of fibrinolysis and coagulation by immunoenzymatic methods in plasma from 20 patients with BP in an active phase and during remission after corticosteroid treatment. The controls were 20 age- and sex-matched healthy subjects. Plasma levels of plasminogen activator inhibitor type 1 (PAI-1) antigen, PAI-1 activity and tissue plasminogen activator (t-PA) antigen were significantly higher in the BP patients with active disease than in healthy controls (P = 0·0001 for all), as were the plasma levels of the fibrin fragment d-dimer and prothrombin fragment F1+2 (P = 0·0001 for both). During remission after treatment, levels of PAI-1 antigen and PAI-1 activity decreased significantly (P = 0·008 and P = 0·006, respectively), and there was also a significant decrease in plasma levels of d-dimer (P = 0·0001) and F1+2 (P = 0·0001). Fibrinolysis is inhibited in patients with active BP, due mainly to an increase in plasma levels of PAI-1. Corticosteroids not only induce the regression of BP lesions, but also reduce the inhibition of fibrinolysis, which may contribute to decreasing thrombotic risk. |
| | |
Authors:
|
A V Marzano; A Tedeschi; I Polloni; C Crosti; M Cugno |
Related Documents
:
|
23226566 - Interactions between serum vitamin d levels and vitamin d receptor gene foki polymorphi... 1333776 - The second international standard for anti-poliovirus sera types 1, 2 and 3. 23639326 - Modification of silicon carbide surfaces by atmospheric pressure plasma for composite a... 23578206 - In vitro assessment, using thrombin generation, of the applicability of prothrombin com... 21804276 - Elevated plasma levels of adropin in heart failure patients. 8674396 - Biochemical effects of oral sodium phosphate. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Clinical and experimental immunology Volume: 171 ISSN: 1365-2249 ISO Abbreviation: Clin. Exp. Immunol. Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2012-12-03 Completed Date: 2013-02-19 Revised Date: 2013-04-16 |
Medline Journal Info:
|
Nlm Unique ID: 0057202 Medline TA: Clin Exp Immunol Country: England |
Other Details:
|
Languages: eng Pagination: 76-81 Citation Subset: IM |
Copyright Information:
|
© 2012 British Society for Immunology. |
Affiliation:
|
Unità Operativa di Dermatologia, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milano, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenal Cortex Hormones
/
therapeutic use Aged Aged, 80 and over Autoimmunity* Blood Coagulation / drug effects, immunology* Female Fibrin Fibrinogen Degradation Products / analysis Fibrinolysis / drug effects, immunology* Humans Male Middle Aged Pemphigoid, Bullous / blood, drug therapy, immunology* Peptide Fragments / blood Plasminogen Activator Inhibitor 1 / blood Protein Precursors / blood Prothrombin Thrombosis / blood, drug therapy, prevention & control Tissue Plasminogen Activator / blood |
| Chemical | |
Reg. No./Substance:
|
0/Adrenal Cortex Hormones; 0/Fibrin Fibrinogen Degradation Products; 0/Peptide Fragments; 0/Plasminogen Activator Inhibitor 1; 0/Protein Precursors; 0/fibrin fragment D; 72270-84-9/prothrombin fragment 1; 78768-79-3/prothrombin fragment 2; 9001-26-7/Prothrombin; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Intestinal anti-tissue transglutaminase antibodies in potential coeliac disease.
Next Document: Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-i...